On the other hand, Gal-1 treatment induces EMT and increases cell invasion involving PI3K and TLR-4 [166], while Gal-1 silencing decreases EMT-related cytokines and suppresses mesenchymal characteristics of LPS-activated colorectal cancer cell lines [167]. The gene discussed is LGALS1; the disease is colorectal cancer.